Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

BAD HOMBURG, Germany, Jan. 9, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion. Under the second tranche, the company plans to repurchase its own shares for a total amount of around EUR 415 million from January ...